Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Target Lowered at Barclays

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective dropped by research analysts at Barclays from $35.00 to $32.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s target price would indicate a potential upside of 100.43% from the company’s current price.

A number of other research analysts have also issued reports on the company. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Canaccord Genuity Group cut their price target on shares of Ultragenyx Pharmaceutical from $39.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday. Guggenheim lowered their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. JPMorgan Chase & Co. downgraded shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $80.00 to $36.00 in a report on Thursday, September 3rd. Finally, Wells Fargo & Company increased their target price on shares of Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Hold” and an average price target of $30.32.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock traded down $1.19 during mid-day trading on Thursday, hitting $15.97. 3,231,126 shares of the stock traded hands, compared to its average volume of 2,874,377. Ultragenyx Pharmaceutical has a twelve month low of $12.73 and a twelve month high of $39.89. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -3.07 and a beta of 0.37. The company’s 50-day simple moving average is $16.45 and its 200-day simple moving average is $22.78.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million during the quarter, compared to the consensus estimate of $182.49 million. The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.81) earnings per share. Analysts forecast that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current year.

Insider Activity

In other news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the sale, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock worth $127,561 over the last quarter. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently bought and sold shares of the stock. Versant Capital Management Inc raised its holdings in Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,001 shares during the period. Quantbot Technologies LP acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth about $48,000. Harbor Investment Advisory LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth about $52,000. Parallel Advisors LLC increased its position in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares in the last quarter. Finally, Leonteq Securities AG increased its position in shares of Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,333 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reported FDA approvals for GENGLYCOS and FAYUVI and agreed to sell two Priority Review Vouchers for a combined $413 million. It also reaffirmed its 2027 profitability outlook and expects R&D expenses in 2027 to be at least 50% below 2025 levels. Third-quarter results and guidance
• Neutral Sentiment: Analyst views were mixed: Canaccord maintained a Buy despite cutting its target to $34; TD Cowen raised its target to $19, and Morgan Stanley raised its target to $22 while retaining Equal Weight. Goldman Sachs and Wedbush lowered their targets to $17 and $22, respectively, with Neutral ratings. Analyst insights
• Negative Sentiment: Third-quarter revenue of $173 million missed analyst expectations of about $182.5 million, and the $1.16-per-share loss was wider than the roughly $1.10 loss expected. Revenue grew 8.2% year over year and the loss narrowed from a year earlier, but the shortfall may weigh on sentiment. Q3 earnings coverage
• Negative Sentiment: A critical investor assessment points to dependence on CRYSVITA, limited contributions from newer launches, and pipeline setbacks. It argues that the path toward profitability relies heavily on deep R&D cuts rather than strong revenue growth. Assessment of Ultragenyx’s outlook

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.